Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Arq. neuropsiquiatr ; 54(1): 82-93, mar. 1996. tab, ilus
Article in English | LILACS | ID: lil-164059

ABSTRACT

Study of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days. Dextrochloropheniramine and ketoprofen were the adjuvant drugs. Multiple symptoms were observed in 90.9 per cent of patients. Intracranial hypertension was manifested in 90.9 per cent. Hydrocephaly occurred in 86.4 per cent. Evolution was satisfactory in 10 patients, 8 died and 4 had sequelae. Tomographic studies showed the appearance of an isolated IVth ventricle in 9 patients, after ventriculoperitoneal shunt, before ABZ treatment in 3 of them, during in 5 and after treatment in one. Median clinical follow-up duration was 10 months for the patients who died and 3-4 years for survivors. In 3 patients there was an increase in cyst size during the administration of the 15 mg/kg/day ABZ dose, which was not observed in any patient when the 30 mg/kg/day dose was used.


Subject(s)
Humans , Male , Female , History, Ancient , Adolescent , Adult , Middle Aged , Albendazole/therapeutic use , Cysticercosis/drug therapy , Central Nervous System Diseases/parasitology , Ketoprofen/therapeutic use , Pheniramine/therapeutic use , Acetazolamide/therapeutic use , Albendazole/administration & dosage , Cysticercosis/cerebrospinal fluid , Cysticercosis/diagnosis , Cysticercosis/surgery , Central Nervous System Diseases/diagnosis , Central Nervous System Diseases/drug therapy , Prognosis , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL